Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A study of a few dozen participants over several weeks cannot reliably rule out uncommon harms or long-term effects
Common IGF-1 LR3 SubQ dose context (research planning, not clinical guidance) Phase Assessment Daily dose 20 mcg/day Frequency Once daily Notes Used to gauge tolerance and hypoglycemic response
In the Phase 2 obesity data the weight curve was still trending downward at 48 weeks, so a genuine plateau at a tolerated maintenance dose may simply reflect the body settling toward a new set point rather than the protocol failing
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
US$ 22.93
US$ 25.22
US$ 21.78
US$ 23.18
